ARID1A缺陷型胃癌的综合分子表型分析揭示广泛的表观基因组重编程及治疗机会
该研究对包括新加坡队列(>200例患者)在内的胃癌患者进行基因组分析,结合单细胞转录组和全基因组ARID1A结合及染色质图谱,揭示ARID1A失活导致启动子H3K27ac增加及NFKB驱动的促炎肿瘤微环境,并证实BRD4和NFKB抑制剂联合靶向在ARID1A突变型胃癌中具有治疗协同作用。
要点
- ARID1A失活在胃癌各分子亚型中普遍存在,与NFKB驱动的促炎肿瘤微环境相关。
- ARID1A缺失导致其占据的远端增强子H3K27ac信号丢失,但NFKB1和NFKB2等基因启动子H3K27ac反而增加。
- BRD4和NFKB抑制剂联合靶向对ARID1A突变型胃癌具有特异性治疗协同作用。
核心结论
- 研究结果提示,针对ARID1A突变型胃癌,可同时靶向肿瘤内在(BRD4相关的启动子激活)和外在(NFKB免疫调节)癌症表型的治疗策略。
研究设计与样本
- 对包括新加坡队列(>200例患者)在内的胃癌患者进行基因组分析,以推导ARID1A失活在不同分子亚型中的突变特征。
- 分析ARID1A突变型胃癌的单细胞转录组图谱,以检查ARID1A缺失引起的肿瘤微环境变化。
- 生成全基因组ARID1A结合和染色质图谱(H3K27ac、H3K4me3、H3K4me1、ATAC-seq),以识别由ARID1A调控的胃特异性表观遗传景观。
- 在基因组、单细胞和表观基因组水平汇聚ARID1A突变型胃癌的独特癌症标志,并通过药理抑制进行靶向。
主要发现
- 观察到ARID1A失活在胃癌各分子亚型中普遍存在,具有不同的突变特征,并与NFKB驱动的促炎肿瘤微环境相关。
- ARID1A缺失导致ARID1A占据的远端增强子处H3K27ac激活信号丢失,但意外地导致ARID1A占据的启动子(如NFKB1和NFKB2基因)处H3K27ac增加。
- ARID1A突变型胃癌中的启动子激活与基因表达增强、BRD4结合增加以及HDAC1和CTCF占据减少相关。
- 通过溴结构域和NFKB抑制剂联合靶向启动子激活和肿瘤炎症,证实了针对ARID1A基因组状态的特异性治疗协同作用。
临床怎么用
- 作者认为,针对ARID1A突变型胃癌,可同时靶向肿瘤内在(BRD4相关的启动子激活)和外在(NFKB免疫调节)癌症表型的治疗策略。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Gastric cancer (GC) is a leading cause of cancer mortality, with ARID1A being the second most frequently mutated driver gene in GC. We sought to decipher ARID1A-specific GC regulatory networks and examine therapeutic vulnerabilities arising from ARID1A loss. DESIGN: Genomic profiling of GC patients including a Singapore cohort (>200 patients) was performed to derive mutational signatures of ARID1A inactivation across molecular subtypes. Single-cell transcriptomic profiles of ARID1A-mutated GCs were analysed to examine tumour microenvironmental changes arising from ARID1A loss. Genome-wide ARID1A binding and chromatin profiles (H3K27ac, H3K4me3, H3K4me1, ATAC-seq) were generated to identify gastric-specific epigenetic landscapes regulated by ARID1A. Distinct cancer hallmarks of ARID1A-mutated GCs were converged at the genomic, single-cell and epigenomic level, and targeted by pharmacological inhibition. RESULTS: We observed prevalent ARID1A inactivation across GC molecular subtypes, with distinct mutational signatures and linked to a NFKB-driven proinflammatory tumour microenvironment. ARID1A-depletion caused loss of H3K27ac activation signals at ARID1A-occupied distal enhancers, but unexpectedly gain of H3K27ac at ARID1A-occupied promoters in genes such as NFKB1 and NFKB2. Promoter activation in ARID1A-mutated GCs was associated with enhanced gene expression, increased BRD4 binding, and reduced HDAC1 and CTCF occupancy. Combined targeting of promoter activation and tumour inflammation via bromodomain and NFKB inhibitors confirmed therapeutic synergy specific to ARID1A-genomic status. CONCLUSION: Our results suggest a therapeutic strategy for ARID1A-mutated GCs targeting both tumour-intrinsic (BRD4-assocatiated promoter activation) and extrinsic (NFKB immunomodulation) cancer phenotypes.
引用
- Xu C, Huang KK, Law JH, et al. Comprehensive molecular phenotyping of ARID1A-deficient gastric cancer reveals pervasive epigenomic reprogramming and therapeutic opportunities. Gut. 2023. PMID: 36918265. doi:10.1136/gutjnl-2022-328332
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。